Expression of Matrix Metalloprotease-9 in Vascular Pericytes in Human Breast Cancer
Overview
Affiliations
Matrix metalloprotease-9 (MMP-9; 92-kd type IV collagenase, gelatinase B) is regarded as important for degradation of the basement membrane and extracellular matrix during cancer invasion and other tissue-remodeling events. Expression of MMP-9 was analyzed in 22 cases of human ductal breast cancer by immunohistochemistry and in 8 of these cases also by in situ hybridization. For immunohistochemistry we used affinity-purified polyclonal antibodies as well as a MMP-9-specific monoclonal antibody (clone 6-6B). Three different stromal cell types with a positive MMP-9 immunoreaction were identified morphologically: neutrophils and macrophage-like cells in all cases and vascular cells in 16 of 22 cases. Double immunofluorescence with antibodies to CD68 conclusively demonstrated MMP-9 expression in macrophages. To identify the positive vascular cells, we employed antibodies to von Willebrand factor and PAL-E for identification of endothelial cells, high molecular weight melanoma-associated antigen for pericytes, and alpha-smooth muscle actin for vascular smooth muscle cells. Using conventional and confocal double immunofluorescence microscopy, colocalization of MMP-9 was seen with high molecular weight melanoma-associated antigen, the pericyte marker, whereas little or no coexpression was seen with alpha-smooth muscle actin. Virtually no coexpression was seen with the endothelial cell markers PAL-E and von Willebrand factor. In situ hybridization showed that MMP-9 mRNA colocalized with MMP-9 immunoreactivity in macrophages and vascular structures, whereas no MMP-9 mRNA was detected in neutrophils. No MMP-9 immunostaining or in situ hybridization signal was detected in cancer cells in any of the cases. Based on these results, it is concluded that MMP-9 in human breast cancer is located in tumor-infiltrating stromal cells, including neutrophils, macrophages, and vascular pericytes, and that the latter two cell types also produce this metalloprotease. We suggest that the MMP-9 produced in pericytes may play a role in extracellular matrix degradation during tumor angiogenesis.
Doronzo A, Porcelli L, Marziliano D, Inglese G, Argentiero A, Azzariti A Medicina (Kaunas). 2023; 59(5).
PMID: 37241104 PMC: 10220815. DOI: 10.3390/medicina59050872.
Brum I, Frigo L, Lana Devita R, Pires J, Hugo Vieira de Oliveira V, Nascimento A Materials (Basel). 2020; 13(20).
PMID: 33076561 PMC: 7602735. DOI: 10.3390/ma13204598.
Park J, Rasch M, Qiu J, Lund I, Egeblad M Neoplasia. 2015; 17(5):421-33.
PMID: 26025665 PMC: 4468371. DOI: 10.1016/j.neo.2015.04.003.
Hua D, Kong W, Zheng X, Zhou Z, Yu B, Li Y Drug Des Devel Ther. 2014; 8:1839-49.
PMID: 25342883 PMC: 4206202. DOI: 10.2147/DDDT.S67305.
Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression.
Farina A, Mackay A Cancers (Basel). 2014; 6(1):240-96.
PMID: 24473089 PMC: 3980597. DOI: 10.3390/cancers6010240.